Colombo R et al. The journey of antibody-drug conjugates: Lessons learned from 40 years of development. Cancer Discov 2024;14(11):2089-108. Abstract
Echarri MJ et al. Efficacy and safety of the addition of prophylactic atropine to patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan: A Spanish multicenter real-world study. San Antonio Breast Cancer Symposium 2024;Abstract P1-06-12.
Freitas S et al. Triple-negative breast cancer with bone marrow involvement and response after use of antibody-drug conjugate (ADC). San Antonio Breast Cancer Symposium 2024;Abstract P1-07-27.
Kudrik F et al. Real-world duration of sacituzumab govitecan-hziy treatment in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium 2024;Abstract P1-07-16.
Lopez E et al. Efficacy analysis & updated safety from the phase 2 PRIMED study of prophylactic granulocyte-colony stimulating factor (G-CSF) & loperamide for patients (pts) with HER2-negative advanced breast cancer (ABC) treated with sacituzumab govitecan (SG). San Antonio Breast Cancer Symposium 2024;Abstract P1-02-06.
Nanda R et al. Management of neutropenia and effectiveness of sacituzumab govitecan (SG) in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated in real-world settings in the United States. San Antonio Breast Cancer Symposium 2024;Abstract P1-09-17.
Poles A et al. Extreme response to sacituzumab-govitecan in a patient with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium 2024;Abstract P1-12-29.
Tarantino P et al. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol 2023;20(8):558-76. Abstract
Tarantino P et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin 2022;72(2):165-82. Abstract
Traina T et al. Real-world treatment patterns and clinical outcomes for patients with metastatic triple-negative breast cancer (mTNBC) in the United States: An electronic health records observational study. San Antonio Breast Cancer Symposium 2024;Abstract P3-08-10.